Jubilant Biosys, a wholly-owned subsidiary of Jubilant Pharmova Limited, has announced a strategic acquisition of an 80% stake in JASMIN, a newly incorporated company in France, as part of its expansion in the research and development (R&D) segment. The remaining 20% equity will be retained by Pierre Fabre SA (PF), a global pharmaceutical and dermo-cosmetic company.
The acquisition follows definitive agreements signed between Jubilant Biosys Innovative Research Services Pte Limited (JBIRSPL), a subsidiary of Jubilant Biosys, and PF. Under this deal, JASMIN will acquire PF’s R&D center, including its R&D site and activities located in Saint Julien, France. The transaction is not subject to foreign investment control in France, as confirmed by the French Ministry of Economy and Finance.
The move is expected to enhance Jubilant’s R&D capabilities and strengthen its footprint in the European market. The company will also execute a Shareholders’ Agreement and other transition agreements with PF to ensure a smooth integration.
The transaction took place at 8:32 PM IST on January 28, 2025. Jubilant Pharmova has formally communicated this development to the stock exchanges, highlighting its commitment to innovation and global expansion in pharmaceutical research.